dienogest has been researched along with Hemorrhage in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K; Kanda, S; Osuga, Y | 1 |
| Akinishi, M; Iwai, K; Kawaguchi, R; Kobayashi, H; Matsubara, S; Nagayasu, M; Niiro, E; Tanase, Y; Yamada, Y | 1 |
1 trial(s) available for dienogest and Hemorrhage
| Article | Year |
|---|---|
Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dysmenorrhea; Female; Hemorrhage; Hormone Antagonists; Humans; Nandrolone; Treatment Outcome | 2020 |
1 other study(ies) available for dienogest and Hemorrhage
| Article | Year |
|---|---|
Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Topics: Adenomyosis; Adult; Contraceptives, Oral, Hormonal; Female; Hemorrhage; Humans; Middle Aged; Nandrolone; Retrospective Studies; Risk Factors | 2019 |